Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
bioAffinity Technologies Inc. Warrant (BIAFW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/22/2025: BIAFW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 63.38% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/22/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.56 | 52 Weeks Range 0.10 - 2.90 | Updated Date 06/14/2025 |
52 Weeks Range 0.10 - 2.90 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -110.55% | Operating Margin (TTM) -141.73% |
Management Effectiveness
Return on Assets (TTM) -88.58% | Return on Equity (TTM) -290.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 21528674 |
Shares Outstanding - | Shares Floating 21528674 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
bioAffinity Technologies Inc. Warrant
Company Overview
History and Background
bioAffinity Technologies, Inc. is a cancer diagnostics and therapeutics company focused on early cancer detection and targeted therapies. While the warrant's history is tied to the underlying company, the warrant's specific issuance date and terms define its individual characteristics.
Core Business Areas
- Early Cancer Diagnostics: Development and commercialization of CyPath Lung, a non-invasive test for early lung cancer detection.
- Targeted Therapies: Research and development of targeted therapeutics based on proprietary technology platforms.
Leadership and Structure
The leadership team consists of experienced executives in diagnostics and biotechnology. Specific details of the organizational structure would require further research.
Top Products and Market Share
Key Offerings
- CyPath Lung: A non-invasive sputum-based test for the early detection of lung cancer. Market share data is still developing as the product is relatively new to the market. Competitors include other diagnostic methods like CT scans and biopsies.
Market Dynamics
Industry Overview
The cancer diagnostics market is growing rapidly, driven by increasing cancer incidence and the demand for early detection and personalized medicine.
Positioning
bioAffinity Technologies aims to be a leader in early cancer detection with its non-invasive CyPath Lung test, offering a potential alternative to more invasive procedures.
Total Addressable Market (TAM)
The global lung cancer diagnostics market is estimated to be in the billions of dollars. bioAffinity is positioned to capture a share of this market with its novel technology.
Upturn SWOT Analysis
Strengths
- Non-invasive diagnostic technology
- Early cancer detection focus
- Experienced leadership team
Weaknesses
- Limited commercialization experience
- Need for further clinical validation
- Competition from established diagnostic methods
Opportunities
- Expanding the use of CyPath Lung in lung cancer screening programs
- Developing new diagnostic tests for other types of cancer
- Partnering with pharmaceutical companies for targeted therapies
Threats
- Regulatory hurdles
- Reimbursement challenges
- Competition from larger diagnostic companies
Competitors and Market Share
Key Competitors
- CGDX
- HOLX
- TMO
Competitive Landscape
bioAffinity is smaller compared to the listed competitors, but it has potential advantages in non-invasive early cancer detection.
Growth Trajectory and Initiatives
Historical Growth: Growth is tied to the underlying stock BIAF.
Future Projections: Future Projections are tied to the underlying stock BIAF and are dependent on market forces.
Recent Initiatives: Recent initiatives are tied to the underlying stock BIAF, these would likely include the commercial roll out of CyPath Lung.
Summary
bioAffinity Technologies shows promise with its CyPath Lung test, but faces significant hurdles in commercialization and competition. Its non-invasive technology offers a potential advantage, but the company needs further clinical validation and market penetration. The warrantu2019s value is therefore highly dependent on the underlying company's success. The company must navigate regulatory hurdles and compete with more established players.
Peer Comparison
Sources and Disclaimers
Data Sources:
- bioAffinity Technologies website
- SEC filings
- Industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About bioAffinity Technologies Inc. Warrant
Exchange NASDAQ | Headquaters San Antonio, TX, United States | ||
IPO Launch date 2022-09-01 | Founder, President, CEO & Director Ms. Maria Zannes J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 57 | Website https://www.bioaffinitytech.com |
Full time employees 57 | Website https://www.bioaffinitytech.com | ||
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.